Status:
ACTIVE_NOT_RECRUITING
Impact of Antihypertensive Therapy on Recurrence Risk of Ovarian Cancer for Bevacizumab-associated Hypertension
Lead Sponsor:
Groupe Hospitalier Pitie-Salpetriere
Collaborating Sponsors:
Dr Floriane Jochum, Principal Investigator
Institut Curie
Conditions:
Ovarian Cancer
Antiangiogenic-Associated Hypertension
Eligibility:
FEMALE
18+ years
Brief Summary
Antiangiogenic therapies like bevacizumab, have notably improved cancer treatment, including for gynecological cancers, by inhibiting the vascular endothelial growth factor and thus limiting tumor gro...
Detailed Description
Antiangiogenic therapies, such as bevacizumab, have significantly improved the treatment landscape of various cancers, including gynecological types. Bevacizumab is a humanized monoclonal IgG1 antibod...
Eligibility Criteria
Inclusion
- women with newly ovarian cancer diagnosis (FIGO III to IV)
- age over 18 years old at time of ovarian cancer diagnosis
- diagnosed between January 1, 2011 and December 31, 2020
- with debulking ovarian cancer surgery and adjuvant chemotherapy
Exclusion
- not in the "Regime general" "Sécurité Sociale" reimbursement system
- without standard chemotherapy protocol (carbotaxol every 3 weeks or weekly)
- history of heart failure or heart surgery, cardiovascular infarction or any coronaropathy disease, cerebro-vascular disease, arteriopathy of the lower limb, within the year before ovarian cancer surgery. Patients with history of hypertension without any complications were not excluded.
- bevacizumab initiation prior to debulking surgery
- combination of antihypertensive classes prior bevaizumab or as the first-line hypertensive therapy of bevacizumab-associated hypertension
- antihypertensive monotherapy from other classes than CCBs and ACEi (ARBs, beta-blockers, diuretics etc...) as the anti-hypertensive therapy. Therapy could be initiated before ovarian surgery.
- Complementary analysis :
- \- patients treated by ARBs
Key Trial Info
Start Date :
May 20 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 31 2024
Estimated Enrollment :
9464 Patients enrolled
Trial Details
Trial ID
NCT06515678
Start Date
May 20 2024
End Date
August 31 2024
Last Update
July 26 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Institut Curie
Paris, France, 75005
2
Pitié-Salpêtrière
Paris, France, 75013